Form 8-K for PEREGRINE PHARMACEUTICALS INC
Other Events, Financial Statements and Exhibits
Item 8.01 Other Events.
On October 15, 2015, Peregrine Pharmaceuticals, Inc. issued a press release announcing that it had expanded its ongoing cancer immunotherapy clinical trial collaboration with AstraZeneca to evaluate the immunotherapy combination of its phosphatidylserine (PS)-targeted immune-activator, bavituximab, and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor, durvalumab (MED14736), in a global Phase II study in patients with previously treated squamous or non-squamous non-small cell lung cancer.
A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:
99.1 Press Release issued October 15, 2015.